KYORIN Pharmaceutical Co., Ltd. (TYO:4569)

Market Cap	84.16B
Revenue (ttm)	130.09B
Net Income (ttm)	9.09B
Shares Out	57.45M
EPS (ttm)	158.16
PE Ratio	9.26
Forward PE	21.80
Dividend	57.00 (3.88%)
Ex-Dividend Date	Mar 28, 2025

Volume	219,100
Average Volume	99,230
Open	1,461.00
Previous Close	1,468.00
Day's Range	1,457.00 - 1,470.00
52-Week Range	1,331.00 - 1,751.00
Beta	-0.06
RSI	43.58
Earnings Date	Jul 31, 2025

About KYORIN Pharmaceutical

KYORIN Pharmaceutical Co., Ltd., through its subsidiaries, researches and develops, manufactures, and sells ethical and generic drugs in Japan and internationally. The company offers Flutiform, a drug for the treatment of asthma; Lyfuna for cough treatment; Desalex, an antiallergic agent; Beova, Uritos, and Imidafenacin KYORIN therapeutic agents for overactive bladder; Lasvic, a quinolone synthetic antibacterial agent; Pentasa, a remedy for ulcerative colitis/Crohn's disease; Nasonex and Mometasone KYORIN, which are used as allergic rhinitis th...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1923
• Employees: 2,042
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4569

Financial Performance

In 2024, KYORIN Pharmaceutical's revenue was 130.09 billion, an increase of 8.83% compared to the previous year's 119.53 billion. Earnings were 9.09 billion, an increase of 70.73%.